[
    [
        {
            "time": "2018-03-15",
            "original_text": "Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study",
            "features": {
                "keywords": [
                    "Cyramza",
                    "Survival Benefit",
                    "Liver Cancer",
                    "Study"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus",
            "features": {
                "keywords": [
                    "FDA",
                    "Refuses",
                    "Alkermes",
                    "Depression Drug",
                    "Review"
                ],
                "sentiment_score": -0.65,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study",
            "features": {
                "keywords": [
                    "Cyramza",
                    "Survival Benefit",
                    "Liver Cancer",
                    "Study"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-05-01",
            "original_text": "CNAT Disappoints, EBIO To Report VISTA Data In May, PRTK To Face FDA In Oct.",
            "features": {
                "keywords": [
                    "CNAT",
                    "Disappoints",
                    "EBIO",
                    "VISTA Data",
                    "PRTK",
                    "FDA"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "CNAT Disappoints, EBIO To Report VISTA Data In May, PRTK To Face FDA In Oct.",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]